References
- Yamamoto T , NakataniM, NarukawaK, ObikaS. Antisense drug discovery and development. Future Med. Chem.3 (3), 339–365 (2011).
- Kurreck J . RNA interference: from basic research to therapeutic applications. Angew. Chem. Int. Ed. Engl.48 (8), 1378–1398 (2009).
- Eckstein F . Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther.24 (6), 374–387 (2014).
- Davis ME , ZuckermanJE, ChoiCHet al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature464 (7291), 1067–1070 (2010).
- Song E , ZhuP, LeeSKet al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol.23 (6), 709–717 (2005).
- Kastelein JJ , RossCJ, HaydenMR. From mutation identification to therapy: discovery and origins of the first approved gene therapy in the western world. Hum. Gene Ther.24 (5), 472–478 (2013).
- Morrissey DV , LockridgeJA, ShawLet al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol.23 (8), 1002–1007 (2005).
- Wooddell CI , RozemaDB, HossbachMet al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther.21 (5), 973–985 (2013).
- De Clercq E . Curious discoveries in antiviral drug development: the role of serendipity. Med. Res. Rev.35 (4), 698–719 (2015).
- Iversen PL , WarrenTK, WellsJBet al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses4 (11), 2806–2830 (2012).
- De Clercq E . Ebola virus (EBOV) infection: therapeutic strategies. Biochem. Pharmacol.93 (1), 1–10 (2015).
- Thi EP , MireCE, LeeACet al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature521 (7552), 362–365 (2015).
- Brake OT , HooftK, LiuYP, CentlivreM, Jasmijn Von EijeK, BerkhoutB. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol. Ther.16 (3), 557–564 (2008).
- Stein EA , PinkertS, BecherPMet al. Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice. J. Infect. Dis.211 (4), 613–622 (2015).
- Grundhoff A , SullivanCS. Virus-encoded microRNAs. Virology411 (2), 325–343 (2011).
- Lindow M , KauppinenS. Discovering the first microRNA-targeted drug. J. Cell Biol.199 (3), 407–412 (2012).
- Lanford RE , Hildebrandt-EriksenES, PetriAet al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science327 (5962), 198–201 (2010).
- Saayman S , AliSA, MorrisKV, WeinbergMS. The therapeutic application of CRISPR/Cas9 technologies for HIV. Expert Opin. Biol. Ther.15 (6), 819–830 (2015).